Avira Therapeutics LLC is categorized under Research and Development Laboratories in Menlo Park, CA and active since 2008.
Avira Therapeutics LLC was established in 2008, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Research and Development Laboratories business, which does work in the B2B market, and is classified as a Research and Development Laboratories, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Ron Geller at the company’s single location by writing to 960 Roble Avenue Apartment C, Menlo Park, California CA 94025 or by phoning (650) 248-1656. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Avira Therapeutics LLC |
| Contact Person: | Ron Geller |
| Address: | 960 Roble Avenue Apartment C, Menlo Park, California 94025 |
| Phone Number: | (650) 248-1656 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2008 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Research and Development Laboratories |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Avira Therapeutics LLC was started in 2008 to provide professional Research and Development Laboratories under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Ron Geller for inquiries that concern Avira Therapeutics LLC by calling the company number (650) 248-1656, as your correspondence is most welcome. Additionally, the physical location of the single location of Avira Therapeutics LLC can be found at the coordinates as well as the street address 960 Roble Avenue Apartment C in Menlo Park, California 94025.
For its online presence, you may visit Avira Therapeutics LLC’s website at and engage with its social media outlets through on Twitter and on Facebook.